My HPRA: Register

The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Opdualag



Bristol-Myers Squibb Pharma EEIGEU/1/22/1679/001

Main Information

Trade NameOpdualag
Active SubstancesRELATLIMAB
Nivolumab
Dosage FormConcentrate for solution for infusion
Licence HolderBristol-Myers Squibb Pharma EEIG
Licence NumberEU/1/22/1679/001

Group Information

ATC CodeL01XY Combinations of antineoplastic agents
L01XY03 Relatlimab Nivolumab

Status

License statusAuthorised
Licence Issued15/06/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - Patient

Patient Card
« Back
Follow medicine

Print